Randomized dual-blind, placebo-controlled study of the effectiveness and safety of Mexidol in the complex therapy of ischemic stroke in the acute period

Author:
V. I. SKBORTSOVA, L. V. STAKHOVSKAYA, Y. R. NARCISSOV, M. K. BODYKHOV, I. ​​V. KICHUK, Y. V. GUDKOVA, T. A. SOLDATENKOVA, T. T. KONDRASHOVA, E. V. KALININA, M. A. NOVICHKOVA, O. B. KERBIKOV

Department of Fundamental and Clinical Neurology of the Russian State Medical University, Research Institute of Cytochemistry and Molecular Pharmacology, Moscow

Place of publication:
STROKE, 18, 2006

Abstract:
The study included 51 patients with ischemic stroke aged 45–85 years who were admitted within the first 24 hours of stroke onset. Mexidol was administered at a dose of 300 mg/day to 24 patients for 14 days from stroke onset. Placebo was administered to 27 patients according to a similar regimen. A significant, accelerated trend in the regression of neurological impairments according to the NIH scale by the 14th day of illness was revealed in the group of patients receiving Mexidol compared to the placebo group (p